Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy

BJU International

Volumn 103, Issue 9, 2009, Pages 1179-1183

  Coward, Robert Matt ^a,b   Simhan, Jay ^a   Carson III, Culley C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Bldg CB#7235   (United States)

Author keywords

Hypogonadism; Prostate cancer; Prostate specific antigen; Testosterone replacement therapy

Indexed keywords

CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DRUG WITHDRAWAL; FOLLOW UP; HEMATOCRIT; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANDROGENS; EPIDEMIOLOGIC METHODS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE;

EID: 64249137805     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08240.x     Document Type: Article

References (21)

1. Raynor MC, Carson CC, Pearson MD, Nix JW. Androgen deficiency in the aging male: a guide to diagnosis and testosterone replacement therapy. Can J Urol 2007 14 : 63 8
2. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract 2002 8 : 439 56
3. Bhasin S, Cunningham GR, Hayes FJ et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006 91 : 1995 2010
4. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001 86 : 724 31
5. Population Division US Census Bureau. Projections of the Population by Selected Age Groups and Sex for the United States: 2010-2050, 2008. Available at: http://www.census.gov/population/www/projections/files/nation/summary/ np2008-t2.xls. Accessed August 2008
6. Araujo AB, O'Donnell AB, Brambilla DJ et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004 89 : 5920 6
7. Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl 2001 22 : 718 31
8. Muller M, van der Schouw YT, Thijssen JH, Grobbee DE. Endogenous sex hormones and cardiovascular disease. J Clin Endocrinol Metab 2003 88 : 5076 86
9. Kupelian V, Page ST, Araujo AB et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006 91 : 843 50
10. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 97
11. Laaksonen DE, Niskanen L, Punnonen K et al. Sex hormone, inflammation, and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003 149 : 601 8
12. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005 174 : 827 34
13. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004 350 : 482 92
14. Jin B, Conway AJ, Handelsman DJ. Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol 2001 54 : 437 45
15. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol 1994 40 : 341 9
16. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003 24 : 299 311
17. Rhoden EL, Morgentaler A. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res 2006 18 : 201 5
18. Wang C, Cunningham G, Dobs A et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004 89 : 2085 98
19. Shabsigh R, Katz M, Yan G, Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 2005 96 : 67M 72M
20. Svatek RS, Shulman MJ, Benaim EA, Rogers TE, Margulis V. Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis. J Urol 2008 179 : 2192 6
21. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006 50 : 935 9